Ashley Olsin
Family Medicine · Dallas, TXNPI 1447771167
Payments from drug & device makers
Across 808 payments — averaging $59.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$33K
- AbbVie$3K
- Pfizer$3K
- Upsher-smith Laboratories LLC$2K
- Teva Pharmaceuticals USA, Inc.$718
- Argenx US, Inc.$548
- plus $6K from 50 others
What the payments were for
- Consulting fees$17,41636%
- Speaking & faculty fees$17,87837%
- Travel & lodging$1,2913%
- Food & beverage$11,79124%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$30,080
- NURTEC ODT$2,320
- ZEMBRACE SYMTOUCH$1,420
- UBRELVY$540
How this compares
$48,376 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 95 | $183,129 |
| Emgality PenGalcanezumab-Gnlm | 205 | $162,085 |
| UbrelvyUbrogepant | 91 | $131,587 |
| QuliptaAtogepant | 82 | $108,607 |
| Aimovig AutoinjectorErenumab-Aooe | 77 | $66,563 |
| Emgality SyringeGalcanezumab-Gnlm | 37 | $26,505 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 22 | $23,185 |
| Ajovy SyringeFremanezumab-Vfrm | 17 | $16,704 |
| Zembrace SymtouchSumatriptan Succinate | 13 | $16,383 |
| Sumatriptan Succinate | 167 | $7,894 |
| Naratriptan Hcl | 73 | $2,584 |
| Frovatriptan Succinate | 12 | $1,799 |
| RizatriptanRizatriptan Benzoate | 112 | $1,529 |
| Gabapentin | 67 | $1,159 |
| Topiramate | 47 | $798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $3,400 | $240,194173 claims |
| PfizerNurtec Odt | $2,946 | $183,12995 claims |
| Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate | $1,946 | $17,18260 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.